Epithelial ovarian cancer is a leading cause of cancer-related death for women both in the
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …

Despite efforts to improve chemotherapeutic efficacy in epithelial ovarian cancer, outcome
for patients with advanced disease has remained unchanged since the introduction of …

Ovarian cancer is an important health concern worldwide. The majority of patients present
with advanced disease, and despite initial chemosensitivity, most relapse and die from their …

Opinion statement Treatment of epithelial ovarian cancer involves surgical management
with staging or debulking surgery and chemotherapy with a platinum and taxane-containing …

Background: There is a critical need to develop effective new strategies for the management
of patients with advanced epithelial ovarian cancer. Objective: The purpose of this …

Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality,
despite advances in surgical and chemotherapeutic management. The molecular pathways …

Introduction: Patients with epithelial ovarian cancer (EOC) have a high rate of recurrence,
and overall survival remains at∼ 25%. There is a need for new treatments that can increase …

Angiogenesis is one of the hallmarks of cancer and plays a crucial role in carcinogenesis
and progression of epithelial ovarian cancer. Antiangiogenic agent is the first approved …

Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the progression
of ovarian cancer through ascites formation and metastatic spread. Bevacizumab (Avastin® …

Data from preclinical and clinical studies reported in the last 2 years demonstrate the
importance of several proangiogenic factors in the prognosis of ovarian cancer, suggesting …